by michael | Jul 30, 2020 | Pharmazz, Press Releases
Abstract The development of effective drugs for stroke is urgently required as it is the 2nd largest killer in the world and its incidence is likely to increase in the future. We have demonstrated cerebral endothelin B receptors (ETBR) as a potential target to treat...
by michael | Jul 22, 2020 | Pharmazz, Press Releases
WILLOWBROOK, Ill., July 20, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced that it has successfully received marketing...
by michael | May 14, 2020 | Pharmazz, Press Releases
WILLOWBROOK, Ill., May 14, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it has received marketing authorization of...
by michael | Apr 27, 2020 | Pharmazz, Press Releases
WILLOWBROOK, Ill., April 27, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that sovateltide, an endothelin-B receptor...
by michael | Apr 13, 2020 | News Articles, Pharmazz
Willowbrook, IL (13 April, 2020) /EMPR.com – Centhaquine: An investigational resuscitative agent that is expected to provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome, reduce multiple...
by michael | Apr 9, 2020 | Pharmazz, Press Releases
WILLOWBROOK, Ill., April 9, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that centhaquine, a drug in final stage of...